Literature DB >> 9715276

Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor.

M M Santoro1, L Penengo, M Minetto, S Orecchia, M Cilli, G Gaudino.   

Abstract

Ron (the receptor for Macrophage Stimulating Protein) has never been implicated before in human malignancies or in cell transformation. In this report we show that Ron can acquire oncogenic potential by means of two amino acid substitutions-D1232V and M1254T-affecting highly conserved residues in the tyrosine kinase domain. The same mutations in Kit and Ret have been found associated with two human malignancies, mastocytosis and Multiple Endocrine Neoplasia type 2B (MEN2B), respectively. Both mutations caused Ron-mediated transformation of 3T3 fibroblasts and tumour formation in nude mice. Moreover, cells transformed by the oncogenic Ron mutants displayed high metastatic potential. The Ron mutant receptors were constitutively active and the catalytic efficiency of the mutated kinase was higher than that of wild-type Ron. Oncogenic Ron mutants enhanced activation of the Ras/MAPK cascade with respect to wild type Ron, without affecting the JNK/SAPK pathway. Expression of Ron mutants in 3T3 fibroblasts led to different patterns of tyrosine-phos-phorylated proteins. These data show that point mutations altering catalytic properties and possibly substrate specificity of the Ron kinase may force cells toward tumorigenesis and metastasis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9715276     DOI: 10.1038/sj.onc.1201994

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  24 in total

1.  Metastatic breast carcinoma to bone disguised by osteopoikilosis.

Authors:  J G Kennedy; J R Donahue; H Aydin; B H Hoang; A Huvos; C Morris
Journal:  Skeletal Radiol       Date:  2003-02-13       Impact factor: 2.199

2.  Identification of protein tyrosine kinases with oncogenic potential using a retroviral insertion mutagenesis screen.

Authors:  Els Lierman; Helen Van Miegroet; Els Beullens; Jan Cools
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941

Review 3.  Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.

Authors:  Omid Zarei; Silvia Benvenuti; Fulya Ustun-Alkan; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-08       Impact factor: 4.553

4.  Characterization of an activated mutant of focal adhesion kinase: 'SuperFAK'.

Authors:  Veronica Gabarra-Niecko; Patricia J Keely; Michael D Schaller
Journal:  Biochem J       Date:  2002-08-01       Impact factor: 3.857

Review 5.  MSP-RON signalling in cancer: pathogenesis and therapeutic potential.

Authors:  Hang-Ping Yao; Yong-Qing Zhou; Ruiwen Zhang; Ming-Hai Wang
Journal:  Nat Rev Cancer       Date:  2013-07       Impact factor: 60.716

6.  SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma.

Authors:  P Cacciotti; R Libener; P Betta; F Martini; C Porta; A Procopio; L Strizzi; L Penengo; M Tognon; L Mutti; G Gaudino
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

7.  Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway.

Authors:  A Danilkovitch-Miagkova; A Miagkov; A Skeel; N Nakaigawa; B Zbar; E J Leonard
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

8.  Protein phosphatase 1 binds to phospho-Ser-1394 of the macrophage-stimulating protein receptor.

Authors:  Massimo M Santoro; Giovanni Gaudino; Emma Villa-Moruzzi
Journal:  Biochem J       Date:  2003-12-15       Impact factor: 3.857

Review 9.  Met-related receptor tyrosine kinase Ron in tumor growth and metastasis.

Authors:  Purnima K Wagh; Belinda E Peace; Susan E Waltz
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

Review 10.  Ron receptor tyrosine kinase signaling as a therapeutic target.

Authors:  Nancy M Benight; Susan E Waltz
Journal:  Expert Opin Ther Targets       Date:  2012-07-26       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.